Clinical Trial Update: Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial comparing capecitabine/tesetaxel to capecitabine/placebo as second-line therapy for gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)
• tesetaxel (tesetaxel)

Snippet

Sponsor: Genta Incorporated | Conditions: Gastric Carcinoma | Phase 2 | Status: UNKNOWN